• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

133例血友病患者中FVIII的功能和免疫分析——轻度A型血友病患者亚组的特征及一期和二期分析的差异

Functional and immunological assays of FVIII in 133 haemophiliacs--characterization of a subgroup of patients with mild haemophilia A and discrepancy in 1- and 2-stage assays.

作者信息

Parquet-Gernez A, Mazurier C, Goudemand M

机构信息

Laboratoire d'Hémostase, Centre Régional de Transfusion Sanguine, Lille, France.

出版信息

Thromb Haemost. 1988 Apr 8;59(2):202-6.

PMID:3133808
Abstract

A systematic study of the levels of FVIII antigen and activity was done in 133 haemophiliacs. No measurable antigen was demonstrated in the 60 severe haemophiliacs, with the exception of 3 patients with levels ranging between 1.5 and 4.5 U/dl, which corresponded to a dramatic FVIII deficiency. The situation was more complex with the 73 moderate and mild haemophiliacs: 39 of them (53.4%) had a partial, concordant deficiency of both the antigen and the procoagulant activity (1- and 2-stage methods), likely corresponding to a decrease in the synthesis of normal FVIII. The conclusion for the other 34 patients, was a qualitative abnormality of FVIII, the levels of antigen in comparison with the procoagulant activity (1-stage method) appearing to be either very reduced (n = 6) or even nil (n = 8), or on the contrary very much higher (n = 20) or normal. For 11 patients in this last category, we found a clear discrepancy between the procoagulant activity levels obtained with the 2 different techniques, the 1-stage levels being higher than the 2-stage levels. This discrepancy which was stable with restudy on multiple occasions and found in different members of the same families was remedied when vWF was absent in one-stage assay. This suggests that we have identified a variant of haemophilia A with an inherited abnormality of FVIII characterized by an in vitro vWF-dependent expression of procoagulant activity.

摘要

对133名血友病患者的FVIII抗原水平和活性进行了系统研究。60名重度血友病患者中,除3名患者的FVIII水平在1.5至4.5 U/dl之间外,未检测到可测量的抗原,这3名患者存在严重的FVIII缺乏。73名中度和轻度血友病患者的情况更为复杂:其中39名(53.4%)患者的抗原和促凝血活性(1期和2期方法)均存在部分一致的缺乏,这可能与正常FVIII合成减少有关。另外34名患者的结论是FVIII存在定性异常,与促凝血活性(1期方法)相比,抗原水平似乎非常降低(n = 6)或甚至为零(n = 8),或者相反非常高(n = 20)或正常。在最后这一组的11名患者中,我们发现两种不同技术获得的促凝血活性水平存在明显差异,1期水平高于2期水平。这种差异在多次复查时稳定,且在同一家族的不同成员中也有发现,当一期试验中缺乏vWF时这种差异得到纠正。这表明我们已经确定了一种A型血友病的变体,其FVIII存在遗传性异常,其特征是促凝血活性在体外依赖vWF表达。

相似文献

1
Functional and immunological assays of FVIII in 133 haemophiliacs--characterization of a subgroup of patients with mild haemophilia A and discrepancy in 1- and 2-stage assays.133例血友病患者中FVIII的功能和免疫分析——轻度A型血友病患者亚组的特征及一期和二期分析的差异
Thromb Haemost. 1988 Apr 8;59(2):202-6.
2
Intranasal DDAVP induced increases in plasma von Willebrand factor alter the pharmacokinetics of high-purity factor VIII concentrates in severe haemophilia A patients.鼻内给予去氨加压素导致血浆血管性血友病因子增加,改变了重度甲型血友病患者高纯度凝血因子VIII浓缩物的药代动力学。
Haemophilia. 1999 Mar;5(2):88-95.
3
Assay discrepancy in mild haemophilia A: entire population study in a National Haemophilia Centre.轻度甲型血友病的检测差异:在一家国家血友病中心进行的全人群研究
Haemophilia. 2009 Jan;15(1):285-9. doi: 10.1111/j.1365-2516.2008.01899.x.
4
One-stage and chromogenic FVIII:C assay discrepancy in mild haemophilia A and the relationship with the mutation and bleeding phenotype.轻度甲型血友病中一步法与显色法FVIII:C检测结果的差异及其与突变和出血表型的关系。
Haemophilia. 2008 Sep;14(5):1049-54. doi: 10.1111/j.1365-2516.2008.01781.x. Epub 2008 Jun 5.
5
DDAVP infusion in haemophilia A carriers: different behaviour of plasma factor VIII and von Willebrand factor.去氨加压素对甲型血友病携带者的输注:血浆凝血因子 VIII 和血管性血友病因子的不同表现
Blood Coagul Fibrinolysis. 1996 Jul;7(5):549-53.
6
In vitro kinetics of factor VIII activity in patients with mild haemophilia A and a discrepancy between one-stage and two-stage factor VIII assay results.轻度甲型血友病患者因子VIII活性的体外动力学以及一期和二期因子VIII检测结果之间的差异
Br J Haematol. 2007 Jan;136(1):138-45. doi: 10.1111/j.1365-2141.2006.06402.x.
7
Altered serum factor VIII-related antigen (VIII : AGN)/von Willebrand factor (VIII : vWf) in haemophiliacs with inhibitors to factor VIII procoagulant activity (VIII : C).血友病患者中抗凝血因子 VIII 促凝活性(VIII : C)的抑制剂对血清 VIII 因子相关抗原(VIII : AGN)/血管性血友病因子(VIII : vWf)的影响。
Thromb Haemost. 1981 Feb 23;45(1):68-72.
8
Quantitative assay of a plasma factor deficient in von Willebrand's disease that is necessary for platelet aggregation. Relationship to factor VIII procoagulant activity and antigen content.对血管性血友病中缺乏的、血小板聚集所必需的一种血浆因子进行定量测定。与凝血因子VIII促凝活性及抗原含量的关系。
J Clin Invest. 1973 Nov;52(11):2708-16. doi: 10.1172/JCI107465.
9
Thrombin generation in haemophilia A patients with mutations causing factor VIII assay discrepancy.血友病 A 患者中导致因子 VIII 检测结果差异的突变与凝血酶生成。
Haemophilia. 2010 Jul 1;16(4):671-4. doi: 10.1111/j.1365-2516.2009.02190.x. Epub 2010 Feb 9.
10
Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1.2型诺曼底隐性血管性血友病:轻度血友病和1型血管性血友病的可变表现。
Acta Haematol. 2009;121(2-3):119-27. doi: 10.1159/000214852. Epub 2009 Jun 8.

引用本文的文献

1
Chromogenic Factor VIII Assay for Patients with Hemophilia A and on Emicizumab Therapy.VIII 因子发色底物分析法在血友病 A 患者及接受艾美赛珠单抗治疗患者中的应用。
Methods Mol Biol. 2023;2663:597-610. doi: 10.1007/978-1-0716-3175-1_39.
2
The Implication of New Developments in Hemophilia Treatment on Its Laboratory Evaluation.血友病治疗新进展对其实验室评估的影响
Cureus. 2022 Oct 12;14(10):e30212. doi: 10.7759/cureus.30212. eCollection 2022 Oct.
3
Life-threatening bleeding in a patient with mild hemophilia A and heterozygosity for von Willebrand disease Type 2N.
一名患有轻度甲型血友病且为2N型血管性血友病杂合子的患者出现危及生命的出血。
Int J Hematol. 2014 Dec;100(6):602-6. doi: 10.1007/s12185-014-1662-3. Epub 2014 Sep 12.
4
Method validation and clinical utility of chromogenic factor VIII assay compared to one-stage assay.发色因子 VIII 检测法与一步法相比的方法验证和临床实用性。
J Thromb Thrombolysis. 2014;37(2):210-5. doi: 10.1007/s11239-013-0910-3.